Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710125 | 0.79 | — | — | |
| SCHEMBL2179497 | 0.79 | — | — | |
| SCHEMBL29775436 | 0.79 | — | — | |
| SCHEMBL17164493 | 0.78 | — | — | |
| SCHEMBL16648831 | 0.76 | CNR1 (0.39) | CYP2D6CYP2C19CA1CA2CA7 | |
| SCHEMBL6722400 | 0.76 | TAS1R3 (0.42) | CYP2D6CYP2C19CA1CA2CA7 | |
| SCHEMBL1120240 | 0.76 | CNR1 (0.39) | CYP2D6CYP2C19CA1CA2CA7 | |
| SCHEMBL1261511 | 0.76 | CNR1 (0.39) | CYP2D6CYP2C19CA1CA2CA7 | |
| SCHEMBL23855050 | 0.74 | ACE (0.41) | CYP2D6CYP2C19CA1CA2CA7 | |
| SCHEMBL15543175 | 0.74 | CYP2D6 (0.36) | CYP2D6CYP2C19CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2646455-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012000608-A2 | NOVEL BETA-AMINOALDEHYDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR CHEMICAL USE AS REACTIVE INTERMEDIATES | GLUESENKAMP KARL-HEINZ (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | CYP2D6 4248/4885CYP2C19 4712/4885CA1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.